Psoriasis | | | | | | | |
| Paul C 2014 | 182 | 44.7 | 31.3 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 12weeks |
| Gordon KB 2016 | 1296 | 45.7 | 31.9 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab 80 mg | 12weeks |
| Gordon KB 2016 | 1224 | 45.0 | 32.9 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab 80 mg | 12weeks |
| Gordon KB 2016 | 1346 | 45.8 | 31.8 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab 80 mg | 12weeks |
| Krueger GG 2007 | 320 | 44.9 | 43.1 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 36weeks |
| Langley RG 2014 | 1306 | 44.4 | 28.9 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 52weeks |
| Langley RG 2014 | 738 | 45.1 | 31.0 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 48weeks |
| Leonardi C 2012 | 142 | 46.2 | 43.0 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab 10, 25,75 or 150 mg | 20weeks |
| Leonardi CL 2008 | 766 | 45.3 | 30.7 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 12weeks |
| Novartis 2010 | 125 | 45.9 | 27.2 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 37weeks |
| Novartis 2012 | 177 | 45.9 | 33.9 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 12weeks |
| Novartis 2015 | 100 | 43.8 | 20.0 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 52weeks |
| Novartis 2017 | 543 | 40.2 | 24.1 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | 52weeks |
| Papp KA 2008 | 1230 | 46.2 | 31.7 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 12weeks |
| Paul C 2015 | 404 | 44.1 | 24.3 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 12weeks |
Psoriatic Arthritis | | | | | | |
| Genovese MC 2013 | 237 | 54.9 | 77.2 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 25, 75, 150 or 300 mg | 20weeks |
| Gottlieb A 2009 | 146 | 48.7 | 43.8 | Phase 2, randomized, crossover assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 63 mg | 12weeks |
| Kavanaugh A 2016 | 312 | 47.9 | 52.6 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 44weeks |
| Kivitz AJ 2019 | 341 | 49.0 | 42.2 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 mg | 112weeks |
| McInnes IB 2013 | 598 | 47.1 | 46.3 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 45 or 90 mg | 108weeks |
| McInnes IB 2015 | 397 | 48.0 | 48.4 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 75, 150 or 300 mg | 52weeks |
| Mease PJ 2015 | 606 | 49.0 | 54.5 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 75 or 150 mg | 24weeks |
| Mease PJ 2017 | 417 | 49.5 | 54.0 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab | 24weeks |
| Nash P 2017 | 363 | 51.9 | 53.4 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ixekizumab 80 mg | 24weeks |
| Nash P 2018 | 414 | 49.8 | 54.8 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 24weeks |
| Novartis 2015 | 42 | 47.0 | 64.3 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 3weeks |
| Van Der Heijde D 2019 | 997 | 48.8 | 49.8 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 24 weeks |
Ankylosing Spondylitis | | | | | | |
| Baeten D 2015 | 371 | 41.8 | 30.7 | Phase 3, randomized, parallel assignment double-blind, placebo-controlled study | Placebo; Secukinumab | 16weeks |
| Baeten D 2015 | 219 | 43.3 | 30.1 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 75 or 150 mg | 16weeks |
| Pavelka K 2017 | 226 | 42.5 | 39.8 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 or 300 mg | 16weeks |
| Kivitz AJ 2019 | 463 | 43.0 | 31.4 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab 150 mg | 16weeks |
Rheumatoid arthritis | | | | | | |
| Blanco FJ 2017 | 551 | 54.5 | 81.7 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 24weeks |
| Tlustochowicz W 2016 | 221 | 54.0 | 79.6 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 16weeks |
| Tahir H 2017 | 637 | 52.9 | 87.3 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Secukinumab | 16weeks |
| Smolen JS 2017 | 274 | 51.5 | 83.2 | Phase 2, randomized, parallel assignment, double-blind, placebo-controlled study | Placebo; Ustekinumab 90 mg | 48weeks |
| Dokoupilova E 2018 | 242 | 54.2 | 83.5 | Phase 3, randomized, parallel assignment, double-blind, placebo-controlled study | 24weeks |